Clinical Trial Update: RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial of RTA 408 ophthalmic suspension for ocular inflammation and pain following ocular surgery has completed, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Inflammation
• Postoperative Pain

Drugs mentioned

• RTA 408 ophthalmic suspension (omaveloxolone)

Snippet

Sponsor: Biogen | Conditions: Inflammation and Pain Following Ocular Surgery | Phase 2 | Status: COMPLETED | Results posted: 2023-04-19